Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ENTA vs CGEM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

CGEM Overall Winner 6-Pillar Tally: ENTA 2 – 3 CGEM (1 Tie) Matrix Metrics: ENTA 2 – 8 CGEM

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENTA carries a Unified Composite Score of 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin), whereas CGEM carries 41.0/100 (SELL) at $9.65 (6.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. CGEM 41.0/100 SELL), CGEM captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (+0.0% vs. -21.6% YoY).
  • Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile CGEM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTA vs CGEM
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.89β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88
CGEM NASDAQ Head-to-Head Winner
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.65
-6.13% 1D
Market Cap $653.8M
TTM Revenue N/A
Forward P/E 6.7x
Beta / 30D Vol 1.58β · 105% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 51.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 29
RSI-14: 28.9 · SMA20: $13.21 · SMA50: $15.62

6-Pillar Scorecard Institutional Category Breakdown (ENTA 2 – 3 CGEM)

Columns: Metric · ENTA · CGEM
1. Valuation Multiples CGEM
Forward P/E 44.0x 6.7x
Trailing P/E 44.0x 6.7x
PEG Ratio N/M N/M
EV / Revenue 5.3x N/M
2. Growth & Scale CGEM
Revenue Growth (YoY) -21.6% +0.0%
Earnings Growth (YoY) -66.2% +0.0%
TTM Revenue (USD) $65M N/A
Market Cap $326.2M $653.8M
3. Profitability & Quality CGEM
Gross Margin 100.0% N/A
Operating Margin -90.0% 0.0%
Net Profit Margin -96.9% 0.0%
Return on Equity (ROE) -70.1% -50.3%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$37M N/A
Cash Flow Margin -56.6% N/A
Net Cash / Leverage $22M Net Debt (0.55x D/E) $4.33 Book/Sh · -50.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 78.7% (11th %ile) 124.5% (9th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTA (2) vs CGEM (8)
Institutional Metric ENTA CGEM Criterion Row Edge
Market Capitalization
Scale
$326.2M $653.8M Larger Scale CGEM
Trailing P/E Ratio
Valuation
44.0x 6.7x Lower Multiple CGEM
Forward P/E Ratio
Valuation
44.0x 6.7x Lower Multiple CGEM
Revenue Growth (YoY)
Growth
-21.6% +0.0% Higher Growth CGEM
Operating Margin (TTM)
Profitability
-90.0% 0.0% Higher Margin CGEM
Net Profit Margin
Profitability
-96.9% 0.0% Higher Margin CGEM
Return on Equity (ROE)
Capital Efficiency
-70.1% -50.3% Higher ROE CGEM
52-Week Range Position
Momentum
10% ($10–$17) 11% ($8–$23) Stronger Trend CGEM
Beta / 30D Volatility
Risk Regime
0.89β · 58% Vol 1.58β · 105% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 41.0 / 100 (SELL) Higher Composite ENTA
Trailing 12M Revenue (USD)
Operating Scale
$65M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$37M ($22M Net Debt (0.55x D/E)) N/A ($4.33 Book/Sh · -50.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTA +22.58 pp
ENTA: -2.79% · CGEM: -25.37%
3M Horizon ENTA +34.82 pp
ENTA: -18.87% · CGEM: -53.69%
6M Horizon ENTA +15.32 pp
ENTA: -19.78% · CGEM: -35.1%
1Y Horizon CGEM +24.63 pp
ENTA: -7.94% · CGEM: +16.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENTA vs CGEM. Trailing 12-month operating profitability (ENTA -90.0% vs CGEM 0.0%) and valuation multiples (ENTA 44.0x vs CGEM 6.7x Forward P/E) are benchmarked directly in Pillar 4 below.

ENTA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$65M
Gross Margin100.0%
Op. Margin-90.0%
ROE / Fwd P/E-70.1% · 44.0x
CGEM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-50.3% · 6.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CGEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGEM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $653.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTA vs CGEM Key Questions & Quantitative Answers

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENTA carries a Unified Composite Score of 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin), whereas CGEM carries 41.0/100 (SELL) at $9.65 (6.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. CGEM 41.0/100 SELL), CGEM captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (+0.0% vs. -21.6% YoY). Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile CGEM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEM leads the Growth & Scale pillar: ENTA posts -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin), compared with CGEM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ENTA generates $65M in USD-normalized revenue versus N/A for CGEM. In operating R&D and SG&A reinvestment, ENTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGEM.

CGEM screens cheaper on headline valuation multiples. ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin), whereas CGEM trades at 6.7x Forward P/E, 6.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTA (-70.1% ROE) versus CGEM (-50.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk). By comparison, CGEM carries 124.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.58β · 105% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.